Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Sep 15 - Sep 20
Fact: You need more than just two nutrients
40 Frameshift, homozygous splicing, and nonsense mutations developed severe phenotypes of PFIC2
Pharmaceutical quality standards
EPS: ~$23.50 Forward P/E: ~42 (premium justified by growth) PEG Ratio: ~0.9 (attractive given growth rate) Long-Term Track Record Performance: 52-Week Range: $623.78 - $999.92 1-Year Return: +20-25% (volatile but trending up) Market Leadership: Approaching $1 trillion valuation Dividend Profile: Current Yield: ~0.6% (modest but growing) Annual Dividend: $6.00 per share Growth Rate: Consistently increasing ~15% CAGR The dividend is small now, but management prioritizes reinvestment in R&D while rewarding long-term shareholders with steady increases
US$ 26.45
US$ 27.08
US$ 27.95
